Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
1.
Antimicrob Agents Chemother ; 58(2): 1127-35, 2014.
Article in English | MEDLINE | ID: mdl-24295985

ABSTRACT

Omadacycline is the first intravenous and oral 9-aminomethylcycline in clinical development for use against multiple infectious diseases including acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), and urinary tract infections (UTI). The comparative in vitro activity of omadacycline was determined against a broad panel of Gram-positive clinical isolates, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), Lancefield groups A and B beta-hemolytic streptococci, penicillin-resistant Streptococcus pneumoniae (PRSP), and Haemophilus influenzae (H. influenzae). The omadacycline MIC90s for MRSA, VRE, and beta-hemolytic streptococci were 1.0 µg/ml, 0.25 µg/ml, and 0.5 µg/ml, respectively, and the omadacycline MIC90s for PRSP and H. influenzae were 0.25 µg/ml and 2.0 µg/ml, respectively. Omadacycline was active against organisms demonstrating the two major mechanisms of resistance, ribosomal protection and active tetracycline efflux. In vivo efficacy of omadacycline was demonstrated using an intraperitoneal infection model in mice. A single intravenous dose of omadacycline exhibited efficacy against Streptococcus pneumoniae, Escherichia coli, and Staphylococcus aureus, including tet(M) and tet(K) efflux-containing strains and MRSA strains. The 50% effective doses (ED50s) for Streptococcus pneumoniae obtained ranged from 0.45 mg/kg to 3.39 mg/kg, the ED50s for Staphylococcus aureus obtained ranged from 0.30 mg/kg to 1.74 mg/kg, and the ED50 for Escherichia coli was 2.02 mg/kg. These results demonstrate potent in vivo efficacy including activity against strains containing common resistance determinants. Omadacycline demonstrated in vitro activity against a broad range of Gram-positive and select Gram-negative pathogens, including resistance determinant-containing strains, and this activity translated to potent efficacy in vivo.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacterial Infections/drug therapy , Enterococcus/drug effects , Escherichia coli/drug effects , Haemophilus influenzae/drug effects , Methicillin-Resistant Staphylococcus aureus/drug effects , Staphylococcus aureus/drug effects , Streptococcus pneumoniae/drug effects , Tetracyclines/pharmacology , ATP-Binding Cassette Transporters/antagonists & inhibitors , ATP-Binding Cassette Transporters/genetics , ATP-Binding Cassette Transporters/metabolism , Animals , Anti-Bacterial Agents/chemical synthesis , Bacterial Infections/microbiology , Drug Resistance, Multiple, Bacterial/drug effects , Enterococcus/growth & development , Escherichia coli/growth & development , Gene Expression , Haemophilus influenzae/growth & development , Male , Methicillin-Resistant Staphylococcus aureus/growth & development , Mice , Microbial Sensitivity Tests , Peritoneum/drug effects , Peritoneum/microbiology , Ribosomes/drug effects , Staphylococcus aureus/growth & development , Streptococcus pneumoniae/growth & development , Tetracyclines/chemical synthesis
2.
Antimicrob Agents Chemother ; 58(3): 1279-83, 2014.
Article in English | MEDLINE | ID: mdl-24041885

ABSTRACT

Omadacycline is a novel first-in-class aminomethylcycline with potent activity against important skin and pneumonia pathogens, including community-acquired methicillin-resistant Staphylococcus aureus (MRSA), ß-hemolytic streptococci, penicillin-resistant Streptococcus pneumoniae, Haemophilus influenzae, and Legionella. In this work, the mechanism of action for omadacycline was further elucidated using a variety of models. Functional assays demonstrated that omadacycline is active against strains expressing the two main forms of tetracycline resistance (efflux and ribosomal protection). Macromolecular synthesis experiments confirmed that the primary effect of omadacycline is on bacterial protein synthesis, inhibiting protein synthesis with a potency greater than that of tetracycline. Biophysical studies with isolated ribosomes confirmed that the binding site for omadacycline is similar to that for tetracycline. In addition, unlike tetracycline, omadacycline is active in vitro in the presence of the ribosomal protection protein Tet(O).


Subject(s)
Anti-Bacterial Agents/pharmacology , Tetracyclines/pharmacology , Bacteria/drug effects , Protein Biosynthesis/drug effects , Ribosomes/drug effects , Tetracycline Resistance
3.
Bioorg Med Chem ; 8(1): 73-93, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10968267

ABSTRACT

As a strategy to increase the penetration of antibiotic drugs through the outer membrane of gram-negative pathogens, facilitated transport through siderophore receptors has been frequently exploited. Hydroxamic acids, catechols, or very close isosteres of catechols, which are mimics of naturally occurring siderophores, have been used successfully as covalently linked escorting moieties, but a much wider diversity of iron binding motifs exists. This observation, coupled to the relative lack of specificity of siderophore receptors, prompted us to initiate a program to identify novel, noncatechol siderophoric structures. We screened over 300 compounds for their ability to (1) support growth in low iron medium of a Pseudomonas aeruginosa siderophore biosynthesis deletion mutant, or (2) compete with a bactericidal siderophore-antibiotic conjugate for siderophore receptor access. From these assays we identified a set of small molecules that fulfilled one or both of these criteria. We then synthesized these compounds with functional groups suitable for attachment to both monobactam and cephalosporin core structures. Siderophore-beta-lactam conjugates then were tested against a panel of Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus strains. Although several of the resultant chimeric compounds had antimicrobial activity approaching that of ceftazidime, and most compounds demonstrated very potent activity against their cellular targets, only a single compound was obtained that had enhanced, siderophore-mediated antibacterial activity. Results with tonB mutants frequently showed increased rather than decreased susceptibilities. suggesting that multiple factors influenced the intracellular concentration of the drugs.


Subject(s)
Anti-Bacterial Agents/pharmacology , Siderophores/pharmacology , Escherichia coli/drug effects , Magnetic Resonance Spectroscopy , Mass Spectrometry , Microbial Sensitivity Tests , Pseudomonas aeruginosa/drug effects , Siderophores/chemistry , Staphylococcus aureus/drug effects , beta-Lactams
4.
Antimicrob Agents Chemother ; 43(12): 2877-80, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10582875

ABSTRACT

The in vitro activity of tobramycin was compared with those of six other antimicrobial agents against 1,240 Pseudomonas aeruginosa isolates collected from 508 patients with cystic fibrosis during pretreatment visits as part of the phase III clinical trials of tobramycin solution for inhalation. The tobramycin MIC at which 50% of isolates are inhibited (MIC(50)) and MIC(90) were 1 and 8 microg/ml, respectively. Tobramycin was the most active drug tested and also showed good activity against isolates resistant to multiple antibiotics. The isolates were less frequently resistant to tobramycin (5.4%) than to ceftazidime (11.1%), aztreonam (11.9%), amikacin (13.1%), ticarcillin (16.7%), gentamicin (19.3%), or ciprofloxacin (20.7%). For all antibiotics tested, nonmucoid isolates were more resistant than mucoid isolates. Of 56 isolates for which the tobramycin MIC was > or = 16 microg/ml and that were investigated for resistance mechanisms, only 7 (12.5%) were shown to possess known aminoglycoside-modifying enzymes; the remaining were presumably resistant by an incompletely understood mechanism often referred to as "impermeability."


Subject(s)
Anti-Bacterial Agents/pharmacology , Cystic Fibrosis/microbiology , Pseudomonas aeruginosa/drug effects , Tobramycin/pharmacology , 4-Quinolones , Anti-Infective Agents/pharmacology , Drug Resistance, Microbial , Humans , Lactams , Microbial Sensitivity Tests , Phenotype , Pseudomonas aeruginosa/genetics , Pseudomonas aeruginosa/isolation & purification
5.
Antimicrob Agents Chemother ; 42(9): 2385-90, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9736568

ABSTRACT

The dynamics of clarithromycin and azithromycin efficacy against pulmonary Haemophilus influenzae infection in rats were evaluated. Efficacy was measured by reduction in pulmonary H. influenzae burden on days 3 and 7 postinoculation. Clarithromycin therapy was effective on day 3 or 7 of therapy, while azithromycin was effective on day 7 but not on day 3 of therapy. Both macrolides produced marked efficacy against all six strains of H. influenzae tested, including four strains for which MICs were above the susceptible breakpoint (8 microgram/ml) concentration of clarithromycin. The two macrolides demonstrated markedly different pharmacokinetic characteristics, with clarithromycin present in both blood and tissue, while azithromycin was concentrated primarily in tissue. During pulmonary infection in rats, H. influenzae was found in both intracellular locations and an extracellular location in the lung. Blood concentrations of clarithromycin and azithromycin approximated human pharmacokinetics, and the blood concentrations for either macrolide rarely exceeded MICs for H. influenzae. At dosages producing blood concentrations similar to values achieved clinically, clarithromycin produced efficacy on day 3 of therapy, while both clarithromycin and azithromycin were equally effective on day 7. The different dynamics of clarithromycin and azithromycin suggest that length of therapy should be considered as a key parameter in evaluations of drug efficacy.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Clarithromycin/therapeutic use , Haemophilus Infections/drug therapy , Haemophilus influenzae , Lung Diseases/drug therapy , Animals , Azithromycin/pharmacokinetics , Clarithromycin/pharmacokinetics , Rats , Rats, Sprague-Dawley
6.
J Antimicrob Chemother ; 40(2): 251-6, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9301991

ABSTRACT

A multi-country clinical trial was conducted in ten European countries to determine the efficacy of clarithromycin-omeprazole dual therapy for treating Helicobacter pylori infection in peptic ulcers. Gastric biopsies were cultured for H. pylori before and after treatment. PCR-RFLP was used to determine the genetic heterogeneity of 100 H. pylori isolates from pretreatment and posttreatment biopsies. An 820 bp amplified fragment of the ureC gene was digested with the restriction enzymes Sau3A and Hhal. Fourteen different Sau3A patterns and 15 different Hhal patterns were identified among the pretreatment isolates. In combination, 42 different RFLP types were identified. Comparison of isolates before treatment with those after treatment showed that five of ten patients on clarithromycin-omeprazole dual therapy had the same RFLP type and that all 12 patients on omeprazole therapy alone had the same RFLP type. All isolates were susceptible to clarithromycin prior to treatment, while seven of ten patients on clarithromycin-omeprazole therapy had H. pylori that was resistant to clarithromycin after therapy and 11 of 12 patients on omeprazole therapy had isolates susceptible to clarithromycin after treatment. In addition to PCR-RFLP typing, the presence of the cytotoxin-associated gene (cagA) and the vacuolating gene (vacA) was determined; 79% of the isolates were cagA-positive and all were vacA-positive. The results of this study indicate that infection of H. pylori in Europe is not restricted to a few RFLP types.


Subject(s)
Antigens, Bacterial , Duodenal Ulcer/microbiology , Genes, Bacterial/genetics , Helicobacter Infections/microbiology , Helicobacter pylori/genetics , Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Bacterial Proteins/genetics , Clarithromycin/therapeutic use , Double-Blind Method , Duodenal Ulcer/drug therapy , Helicobacter Infections/drug therapy , Helicobacter pylori/classification , Helicobacter pylori/drug effects , Humans , Omeprazole/therapeutic use , Polymerase Chain Reaction , Polymorphism, Restriction Fragment Length
7.
J Antimicrob Chemother ; 40(2): 283-6, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9301997

ABSTRACT

Fifty-four of 59 (91.5%) clarithromycin-resistant isolates of Helicobacter pylori from different patients possessed either the A2143G (formerly A2058G) or the A2144G (formerly A2059G) mutation in the gene encoding 23S rRNA. The A2143G mutation was significantly more likely to occur in isolates with MICs exceeding 64 mg/L (65% versus 30% with the A2144G mutation; P = 0.01). The majority (26 of 31; 83.9%) of isolates with the A2143G mutation had MICs exceeding 64 mg/L. Peptic ulcer disease recurred in a substantial proportion of patients infected with H. pylori strains containing either the A2143G or the A2144G mutation.


Subject(s)
Anti-Bacterial Agents/pharmacology , Clarithromycin/pharmacology , Helicobacter pylori/genetics , Point Mutation/genetics , RNA, Bacterial/genetics , RNA, Ribosomal, 23S/genetics , DNA, Bacterial/analysis , Drug Resistance, Microbial/genetics , Helicobacter pylori/drug effects , Humans , Polymerase Chain Reaction
8.
J Clin Microbiol ; 35(6): 1311-5, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9163435

ABSTRACT

The National Committee for Clinical Laboratory Standards (NCCLS) methods for susceptibility testing of Haemophilus influenzae in Haemophilus test medium allow a pH range of 7.2 to 7.4. However, it is known that bacteria may appear to be less susceptible to macrolides at lower pHs. Forty-four strains of H. influenzae were tested for their susceptibilities to clarithromycin and azithromycin by the disk diffusion and broth microdilution methods. The isolates appeared to be less susceptible at pH 7.2 than at pH 7.4 by both methods. Clarithromycin was less active at pH 7.2 against 43% of the isolates by the disk diffusion method and against 52% of the isolates by the broth microdilution method. Similarly, azithromycin was less active at pH 7.2 against 41 and 45% of the isolates by the disk diffusion and broth microdilution methods, respectively. Forty-two isolates were classified as clarithromycin susceptible and all isolates were classified as azithromycin susceptible by the disk diffusion method, regardless of the medium pH. However, only 21 isolates were clarithromycin susceptible at pH 7.2 and 34 isolates were susceptible at pH 7.4 by the broth microdilution method, even though quality control results indicated valid testing at both pHs. This study indicated that the results of tests of the susceptibility of H. influenzae with clarithromycin and azithromycin are highly dependent on the pH of the medium. Test results and their interpretations varied even when the medium pH was within the NCCLS-approved range and, coupled with the current NCCLS breakpoint of 8 microg/ml in the case of clarithromycin, may explain some of the observed discordances between the disk diffusion and broth microdilution methods.


Subject(s)
Anti-Bacterial Agents/pharmacology , Azithromycin/pharmacology , Clarithromycin/pharmacology , Haemophilus influenzae/drug effects , Microbial Sensitivity Tests/standards , Hydrogen-Ion Concentration , Microbial Sensitivity Tests/methods
9.
Epidemiol Infect ; 118(2): 119-24, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9129588

ABSTRACT

A clinical trial was conducted in Argentina to determine the efficacy of clarithromycin plus lansoprazole for the treatment of Helicobacter pylori in duodenal ulcers and non-ulcer dyspepsia. PCR-RFLP was conducted on an 820-bp amplified product of the ureC gene of H. pylori to determine the genetic heterogeneity of 83 pretreatment and 21 post-treatment isolates. Twelve different restriction patterns were observed when digested with Sau 3A or Hha I, resulting in 40 different RFLP types. Comparison of isolates before treatment to after treatment showed that 20 of 20 patients had the same RFLP type. In addition, the presence of the cytotoxin-associated gene (cagA) and the vacuolating gene (vacA) were determined. All pretreatment isolates were positive for vacA whereas 75% of the pretreatment isolates were positive for cagA. The results of this study indicate that a high degree of heterogeneity exists among H. pylori and that infection is not limited to a small number of RFLP types.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Antigens, Bacterial , Bacterial Proteins/drug effects , Bacterial Proteins/genetics , Clarithromycin/therapeutic use , Genes, Bacterial/drug effects , Helicobacter Infections/microbiology , Helicobacter pylori/classification , Helicobacter pylori/genetics , Protein Synthesis Inhibitors/therapeutic use , Stomach Diseases/microbiology , Bacterial Proteins/biosynthesis , Biopsy , DNA Probes , Helicobacter Infections/drug therapy , Humans , Polymerase Chain Reaction/methods , Polymorphism, Restriction Fragment Length , Reproducibility of Results , Serotyping/methods , Stomach Diseases/drug therapy
10.
Antimicrob Agents Chemother ; 41(3): 712-4, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9056021

ABSTRACT

We have developed a rapid PCR-oligonucleotide ligation assay that can discriminate single base substitutions that are associated with clarithromycin resistance in Helicobacter pylori. Susceptible isolates were wild type at positions 2143 and 2144 (cognate to 2058 and 2059 in Escherichia coli), while 93% of the resistant isolates contained A-to-G mutations at either position and 7% of the isolates contained A-to-C mutations at position 2143. In addition, the MIC for 86% of the resistant isolates with an A2143 mutation was > or = 64 micrograms per ml, and that for 89% of the resistant isolates with an A2144 mutation was < or = 32 micrograms per ml.


Subject(s)
Anti-Bacterial Agents/pharmacology , Clarithromycin/pharmacology , Helicobacter pylori/drug effects , Helicobacter pylori/genetics , Mutation/physiology , RNA, Ribosomal, 23S/genetics , Drug Resistance, Microbial/genetics , Oligonucleotide Probes , Polymerase Chain Reaction , RNA Probes , rRNA Operon
11.
J Clin Microbiol ; 35(2): 471-3, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9003618

ABSTRACT

The molecular typing of 81 pretreatment Helicobacter pylori isolates and the comparison of 18 pretreatment-posttreatment pairs is described by restriction fragment length polymorphism (RFLP) of the ureC gene. The results of our study show the extreme genomic diversity of H. pylori and indicate that infection by H. pylori in the United States does not appear to be limited to a small number of RFLP types.


Subject(s)
Antigens, Bacterial , Bacterial Typing Techniques , Genes, Bacterial , Helicobacter Infections/microbiology , Helicobacter pylori/classification , Polymorphism, Restriction Fragment Length , Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Bacterial Proteins/genetics , Clarithromycin/therapeutic use , Double-Blind Method , Duodenal Ulcer/drug therapy , Duodenal Ulcer/microbiology , Helicobacter Infections/drug therapy , Helicobacter pylori/genetics , Humans , Omeprazole/therapeutic use , Open Reading Frames , United States
12.
Helicobacter ; 1(4): 227-8, 1996 Dec.
Article in English | MEDLINE | ID: mdl-9432314

ABSTRACT

BACKGROUND: Transition mutations (A-G) at residue 2143, cognate to position 2058 in the Escherichia coli 23S rRNA gene, have been shown to confer resistance to macrolides in Helicobacter pylori. This study reports the finding that transversion mutations (A-C) can occur at 2143 as well. MATERIALS AND METHODS: Three clarithromycin-resistant H. pylori isolated from three different patients after treatment with clarithromycin were analyzed for point mutations by cycle sequencing of a 163-bp amplified region surrounding residue 2143 within the conserved loop of the 23S rRNA gene. RESULTS: Nucleotide sequence comparisons of a 163-bp amplified product revealed that A-C transversion mutations occurred at position 2143. H. pylori isolated from the patients prior to treatment were susceptible to clarithromycin and displayed no polymorphism at 2143. CONCLUSION: This is the first report to show that A-C transversion mutations at position 2143 can confer resistance to clarithromycin in H. pylori and further support the role that mutations at position 2143 play in conferring macrolide resistance in H. pylori.


Subject(s)
Clarithromycin/pharmacology , DNA, Bacterial/genetics , DNA, Ribosomal/genetics , Helicobacter Infections/microbiology , Helicobacter pylori/drug effects , Point Mutation , RNA, Bacterial/genetics , RNA, Ribosomal, 23S/genetics , Drug Resistance, Microbial/genetics , Helicobacter pylori/isolation & purification , Humans , Polymerase Chain Reaction
13.
Am J Gastroenterol ; 91(11): 2347-54, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8931416

ABSTRACT

OBJECTIVES: The goals of the study were 1) to evaluate the efficacy of clinically relevant antibacterial therapies in the ferret model of Helicobacter-induced gastritis and 2) to compare these results to the efficacy achieved clinically in humans. METHODS: Ferrets were inoculated with H. mustelae, and gastritis was allowed to develop. The double therapy of clarithromycin and omeprazole and the triple therapies of clarithromycin or amoxicillin with metronidazole and omeprazole were administered. Efficacy was evaluated by Helicobacter burden cultured from biopsy samples and by histopathological evaluation of Helicobacter burden and gastric inflammation with pylorus and fundus samples obtained 4 wk after the end of antibacterial therapy. RESULTS: Clarithromycin-based double and triple therapies significantly reduced Helicobacter burden and decreased gastric inflammation. Clarithromycin-based double therapy was more effective than amoxicillin-based triple therapy. Reduction of the length of clarithromycin therapy from 14 to 7 days decreased efficacy. Antibacterial therapies in the ferret did not produce eradication rates comparable to clinical results, even though the serum concentrations of clarithromycin in ferret were in excess of concentrations used in humans. Relapse of Helicobacter infection after the end of therapy occurred in some cases. CONCLUSIONS: Although the ferret model of Helicobacter gastric infection underestimated the clinical efficacy of antibacterial treatments in humans, the model was valuable for comparing the relative efficacy of antibacterial therapies.


Subject(s)
Ferrets , Gastritis/microbiology , Helicobacter Infections/drug therapy , Amoxicillin/therapeutic use , Animals , Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Clarithromycin/therapeutic use , Disease Models, Animal , Drug Therapy, Combination , Female , Gastric Mucosa/microbiology , Gastric Mucosa/pathology , Gastritis/drug therapy , Gastritis/pathology , Helicobacter/classification , Helicobacter/drug effects , Helicobacter Infections/pathology , Metronidazole/therapeutic use , Microbial Sensitivity Tests , Omeprazole/therapeutic use , Penicillins/therapeutic use , Time Factors
14.
J Antimicrob Chemother ; 38(4): 641-53, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8937959

ABSTRACT

ABT-719 is a 2-pyridone antimicrobial which inhibits DNA gyrase activity. It has considerable subcutaneous (sc) and oral efficacy in the treatment of experimental pyelonephritis induced in carrageenan-treated mice by clinical isolates of Enterococcus faecalis, Enterococcus faecium, Escherichia coli, and Pseudomonas aeruginosa. Therapeutic ED50s, defined here as producing a 2 log10 reduction in kidney bacterial burden, provide a reliable end point for comparison of drug efficacy in this experimental infection. Therapeutic ED50s for ABT-719 against these infections were equal to or up to ten-fold lower than those for ciprofloxacin, used as a reference because of similarity in mode of action. Against E. faecalis, the therapeutic ED50s for ABT-719 were 4.5-13.6 mg/kg.day for sc administration and 6.8-8.9 mg/kg.day for oral administration. ABT-719 was more potent than ciprofloxacin and vancomycin against the E. faecalis strains, which showed ciprofloxacin and vancomycin resistance covering a range of MICs. Against E. faecium, the therapeutic ED50s for ABT-719 were 8.8 mg/kg.day (sc) and 9.4 mg/kg.day (oral). Against an isolate of E. faecium showing ciprofloxacin and vancomycin resistance the ED50 for ABT-719 to achieve a 1 log10 reduction in kidney bacterial burden was 17.9 mg/kg.day by sc administration. While ABT-719 had lower efficacy against this isolate than against others, ciprofloxacin and vancomycin failed to show efficacy. Against E. coli, the therapeutic ED50 for ABT-719 was 1.1 mg/kg.day (oral), and against P. aeruginosa, this value was 2.7 mg/kg.day (oral) with values against both of these pathogens similar to those for ciprofloxacin. ABT-719, which represents the new 2-pyridone compound class, has promise for the treatment of urinary tract infections, as suggested by the significant efficacy seen against experimental pyelonephritis caused by E. coli, P. aeruginosa and susceptible and resistant enterococci.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Enterococcus/drug effects , Escherichia coli/drug effects , Pseudomonas aeruginosa/drug effects , Pyelonephritis/drug therapy , Animals , Anti-Bacterial Agents/pharmacokinetics , Anti-Infective Agents/therapeutic use , Drug Evaluation, Preclinical , Female , Fluoroquinolones , Kidney/drug effects , Kidney/metabolism , Mice , Mice, Inbred Strains , Microbial Sensitivity Tests , Pyelonephritis/metabolism , Pyelonephritis/microbiology , Pyridones/pharmacokinetics , Pyridones/therapeutic use , Treatment Outcome
15.
J Antimicrob Chemother ; 38(4): 719-25, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8937967

ABSTRACT

We evaluated the activity of clarithromycin, 14-OH clarithromycin, amoxycillin, bismuth, metronidazole and ciprofloxacin against six strains of Helicobacter pylori to determine if there were differences in response to these antimicrobial agents during growth in vitro. Clarithromycin and its 14-hydroxy-metabolite exhibited an early bactericidal activity with at least a 3 log10 reduction after 2-8 incubation. Exposure to bismuth, ciprofloxacin and metronidazole resulted in a > 3 log reduction by 24 h with the greatest decrease in viability occurring between 8 and 24 h. The viable count of three strains was reduced by a 1-2 log10 after 24 h exposure to amoxycillin and by a > 3 log10 after 48 h.


Subject(s)
Anti-Bacterial Agents/pharmacology , Helicobacter pylori/drug effects , Amoxicillin/pharmacology , Ciprofloxacin/pharmacology , Clarithromycin/analogs & derivatives , Clarithromycin/pharmacology , Helicobacter pylori/growth & development , Humans , Kinetics , Logistic Models , Metronidazole/pharmacology , Microbial Sensitivity Tests , Organometallic Compounds/pharmacology
16.
Diagn Microbiol Infect Dis ; 26(2): 73-8, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8985659

ABSTRACT

The mechanism of macrolide resistance was examined in 73 clinical isolates of Streptococcus pneumoniae. Two distinct resistance phenotypes were observed: high-level macrolides-lincosamides-streptogramin B (MLS) resistance and low-level macrolide resistance with lincosamide susceptibility. High-level MLS resistance was associated with the presence of ermAM. Strains with the low-level resistant phenotype (novel) were negative for ermA, ermC, ermAM, ereA, ereB and msrA by polymerase chain reaction (PCR) amplification with gene-specific primers. Ribosomes isolated from novel strains bound the same amount of [14C]-erythromycin as ribosomes from sensitive strains. These novel strains also did not inactivate the macrolide. The novel mechanism was found in 41% of the erythromycin resistant S. pneumoniae examined.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Microbial/genetics , Membrane Transport Proteins , Streptococcus pneumoniae/drug effects , Bacterial Proteins , Biological Assay , Carboxylic Ester Hydrolases/genetics , Clindamycin/pharmacology , DNA Primers , Erythromycin/antagonists & inhibitors , Erythromycin/pharmacology , Genes, Bacterial , Microbial Sensitivity Tests , Polymerase Chain Reaction , Ribosomes/drug effects , Ribosomes/metabolism , tRNA Methyltransferases/genetics
17.
Antimicrob Agents Chemother ; 40(2): 477-80, 1996 Feb.
Article in English | MEDLINE | ID: mdl-8834903

ABSTRACT

Twelve clarithromycin-resistant Helicobacter pylori isolates (100% of resistant isolates examined) from seven different patients each contained an A-->G transition mutation within a conserved loop of 23S rRNA. A-->G transition mutations at positions cognate with Escherichia coli 23S rRNA positions 2058 and 2059 were identified. Clarithromycin-susceptible H. pylori isolates from 14 different patients displayed no polymorphisms in a conserved loop within domain V of 23S rRNA. The study is the first to report mutations in H. pylori associated with resistance to an antimicrobial agent used in established peptic ulcer treatment regimens.


Subject(s)
Anti-Bacterial Agents/pharmacology , Clarithromycin/pharmacology , Helicobacter pylori/drug effects , Helicobacter pylori/genetics , Protein Synthesis Inhibitors/pharmacology , RNA, Ribosomal, 23S/drug effects , RNA, Ribosomal, 23S/genetics , Base Sequence , Drug Resistance, Microbial , Electrophoresis, Agar Gel , Helicobacter pylori/isolation & purification , Microbial Sensitivity Tests , Molecular Sequence Data , Mutation , Sequence Homology, Nucleic Acid
18.
Diagn Microbiol Infect Dis ; 24(1): 37-41, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8988762

ABSTRACT

The optimal method for the determination of the minimum inhibitory concentration (MIC) of antimicrobials against Helicobacter pylori has not been established. The epsilometer agar diffusion gradient test (E-Test; AB Biodisk, Solna, Sweden) was compared with broth microdilution, the reference method, and disk diffusion for the antimicrobial susceptibility testing of 122 clinical isolates of H. pylori to ampicillin, clarithromycin, and metronidazole. Isolates were considered to be resistant when the MIC values was > 8 micrograms/ml for either ampicillin or metronidazole and > 2 micrograms/ml for clarithromycin. For an individual isolate, the MICs for ampicillin and clarithromycin determined by broth microdilution and the E-test were highly reproducible, with replicate results being within +/- 1 log2 dilution. The correlation between the MICs determined by E-test and broth microdilution was excellent for both ampicillin and clarithromycin (90.1% and 88.5% were within +/- log2 dilution, and 98.3% and 96.7% of the values were within +/- 2 log2 dilution, respectively). In no instance did the interpretation of "sensitive" or "resistant" differ. Conversely, only 70.5% of the E-test results of metronidazole were within +/- 1 log2 dilution of the broth microdilution results. In addition, 15 (12.3%) of the H. pylori isolates interpreted as resistant by the E-test were sensitive by the broth microdilution method. All discrepancies occurred when the E-test MIC values fell between 8 and 32 micrograms/ml. The results of the ampicillin and clarithromycin disk diffusion assay correlated 100% with the results of the broth microdilution. However, these data suggest that when the E-test MIC results of metronidazole yield values between 8 and 32 micrograms/ml, the MIC should be reevaluated by another method.


Subject(s)
Ampicillin/pharmacology , Anti-Bacterial Agents/pharmacology , Antitrichomonal Agents/pharmacology , Clarithromycin/pharmacology , Helicobacter pylori/drug effects , Metronidazole/pharmacology , Microbial Sensitivity Tests/methods , Penicillins/pharmacology
19.
Antimicrob Agents Chemother ; 39(4): 964-70, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7786004

ABSTRACT

ABT-719 (A-86719.1) is the first compound of a new class of novel DNA gyrase inhibitors, the 2-pyridones, with potent antibacterial activity against gram-positive, gram-negative, and anaerobic organisms. ABT-719 was more active than ciprofloxacin, sparfloxacin, and clinafloxacin against gram-positive bacteria. ABT-719 was particularly active against Staphylococcus aureus (MIC at which 90% of the isolates were inhibited [MIC90] = 0.015 micrograms/ml) and Streptococcus pneumoniae (MIC90 = 0.03 micrograms/ml). ABT-719 was also the most active of the compounds tested against ciprofloxacin-resistant S. aureus isolates, with an MIC90 of 0.25 micrograms/ml, compared with 64 micrograms/ml for ciprofloxacin. Against gram-negative organisms, ABT-719 was as active as or slightly more active than ciprofloxacin and was the most active compound against ciprofloxacin-resistant Pseudomonas aeruginosa (MIC90 = 2.0 micrograms/ml). ABT-719 was also the most active compound against both gram-positive and gram-negative anaerobes, with MIC90s ranging from 0.12 to 0.25 micrograms/ml.


Subject(s)
Anti-Bacterial Agents/pharmacology , Topoisomerase II Inhibitors , Bacteria/drug effects , Microbial Sensitivity Tests , Pyridones/pharmacology
20.
Antimicrob Agents Chemother ; 38(5): 1071-8, 1994 May.
Article in English | MEDLINE | ID: mdl-8067740

ABSTRACT

A-80556 is a novel fluoroquinolone with potent antibacterial activity against gram-positive, gram-negative, and anaerobic organisms. A-80556 was more active than ciprofloxacin, ofloxacin, lomefloxacin, and sparfloxacin against gram-positive bacteria. A-80556 was particularly active against Staphylococcus aureus (MIC for 90% of isolates [MIC90], 0.12 microgram/ml, relative to fluoroquinolone-susceptible strains) and Streptococcus pneumoniae (MIC90, 0.12 microgram/ml). A-80556 was also the most active of the quinolones tested against ciprofloxacin-resistant S. aureus, with an MIC90 of 4.0 micrograms/ml; that of ciprofloxacin was > 128 micrograms/ml. However, the significance of this activity is not known. A-80556 was slightly less active against Escherichia coli (MIC90, 0.06 microgram/ml) and other enteric organisms than ciprofloxacin (MIC90 for E. coli, < or = 0.03 microgram/ml). A-80556 was slightly less active against Pseudomonas aeruginosa (MIC90, 4.0 micrograms/ml) than ciprofloxacin (MIC90, 2.0 micrograms/ml) and more active against Acinetobacter spp. (respective MIC90s, 0.12 and 0.5 microgram/ml). A-80556 was also the most active compound against anaerobes. Against Bacteroides fragilis, the MIC90 of A-80556 was 2.0 micrograms/ml; that of ciprofloxacin was 16 micrograms/ml. The in vivo efficacy of A-80556 in experimental models with both gram-positive and gram-negative infections was consistent with the in vitro activity and pharmacokinetics and oral absorption in mice.


Subject(s)
Anti-Infective Agents/pharmacology , Bacteria/drug effects , Bacterial Infections/drug therapy , Fluoroquinolones , Quinolones/pharmacology , Animals , Anti-Infective Agents/pharmacokinetics , Anti-Infective Agents/therapeutic use , Bacteria, Anaerobic/drug effects , Bacterial Infections/microbiology , Drug Resistance, Microbial , Female , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Mice , Mice, Inbred Strains , Microbial Sensitivity Tests , Quinolones/pharmacokinetics , Quinolones/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL